US Biotech, HiberCell, Acquires Genuity Science. Read more here.

Precision Health Initiative
Data Controller

Genuity Science (Ireland) Limited is responsible for the management and control of all EU Research Data in the Precision Health Initiative.
We are deeply committed to the ethical and responsible stewardship and use of all Research Data in a safe and secure manner in compliance with all applicable laws, including GDPR and the Irish Health Research Regulations.

Board of Directors

David Kavanagh, PhD,
Board Director

VP Clinical Operations,
Genuity Science
Managing Director,
Genuity Science (Ireland) Ltd.

“Genomics is the key to unlocking the potential of precision medicine.”

David leads Genuity Science’s global clinical operations and programmes and is the managing director of our Ireland site. David is primarily responsible for the establishment and management of long-term research partnerships with world leading health systems, biobanks and cohort research groups. The work of David and his team supports the ethical and responsible sourcing of human biological samples and deep phenotype data, the downstream project management of related genomic analysis projects and the support of the ongoing needs of our academic and healthcare partners. The team’s efforts ensure that our research teams have access to the highest quality data in order to deliver breakthrough insights to our pharma and biotech customers.
David has extensive experience in life sciences and has held leadership roles in several high-growth academic and commercial life science organisations including Systems Biology Ireland, located at University College Dublin and CompareNetworks, a San Francisco-based life science marketing company.  David’s areas of specialty include life science innovation and commercialisation, operational & high performing team development in life science start-up environments, genomics, systems biology, connected health, life science text mining and healthcare consulting.
David holds a PhD in Biochemistry from University College Dublin.

Alan Rigby, PhD,
Board Director

Co-Founder, President & Chief Executive Officer, HiberCell

Alan Rigby is the Co-Founder, President and CEO of Genuity Science’s parent company, HiberCell. Alan is a passionate and innovative oncology leader with over 20 years of academic and industry experience in the area of data driven oncology drug discovery from concept to clinical candidate to genetically enabled first-in-man studies. He is committed to responsibly leveraging clinical material and data for use in the identification, stratification and development of ‘next generation’ cancer therapeutics for use in responder populations. This ‘commitment’ has resulted in clinically validated large and small molecule therapeutics for several cancer indications. Most recently, Alan led a prioritised and focused effort to translate ‘Natures Intracellular Biologic’ into transformative medicines for oncology and antibiotic resistance while chief scientific officer of Warp Drive Bio., a Cambridge based biotechnology company that was recently acquired. Alan joined Warp Drive Bio following a tenure as senior vice president and chief scientific officer at Synta Pharmaceuticals. While at Synta Alan led research and development efforts for Synta’s HSP90 clinical candidate, Ganetespib, as well as restructuring the preclinical small molecule drug conjugate platform. Prior to joining Synta, Alan was vice president, global antibody drug conjugate biology, and head of external innovation for oncology research at the New York site for Eli Lilly and Company. Before launching his biotech/ pharmaceutical career, he was a National Institutes of Health (NIH) funded assistant professor and principal investigator at Beth Israel Deaconess Medical Center, Harvard Medical School. While at Harvard Medical School, he founded and directed the Drug Discovery and Target Validation Program within the Beth Israel Deaconess Medical Center. As a mentor and advisor Alan continues to work with numerous organisations to assemble and chair scientific conferences with a focus on translating innovative science and oncology-centric platforms into robust and durable clinically validated strategies.
Alan is on the Editorial Advisory Board for Future Medicinal Chemistry, was North American Editor for Current Computer Aided Drug Discovery and has published more than 55 scientific papers, a book chapter and has 12 patents that have published or are pending. He holds an Honours BSc. in Biochemistry from the University of Western Ontario in London, Ontario, Canada and a Ph.D. in Biochemistry from the same University.

Colin Beecham
Board Director

SVP, Finance, Genuity Science

Colin joined Genuity Science in 2015 overseeing all aspects of finance and administration for the Irish entity (Genomics Medicine Ireland Ltd.). He played a major role in building GMI from its inception including the integration and restructure of GMI into Genuity Science, and is a key business leader in the organisation.
Prior to joining the company, Colin worked in senior financial positions in global manufacturing companies, initially in the UK and other parts of Europe. In Ireland, he has worked for a number of companies, helping them to solve issues, create value, maximise growth and improve business performance. His experience crosses many multi-functional areas and has been applied to the rapid scaling of Genuity Science.
Colin is a Qualified Accountant and Treasurer, and he received his Economics and Law degree from Durham University, England.